Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone)
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study was to assess the clinical outcome of patients with a mild to
moderate IPF after a one-year therapy with Esbriet® (Pirfenidone).